Pyxis secured S$13 million in the first close of its S$18 million growth funding round, reflecting strong investor confidence in its vessel technology, commercial traction, and regional growth ...

Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell ...

Investing.com -- Pyxis Oncology Inc (NASDAQ:PYXS) stock tumbled 49.9% in premarket trading Thursday after investors expressed disappointment with preliminary data from the company’s experimental ...

BOSTON - Pyxis Oncology, Inc. (NASDAQ:PYXS) announced preliminary data from ongoing Phase 1 clinical studies of its antibody-drug conjugate micvotabart pelidotin (MICVO) in patients with ...

BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced positive ...

The DNP Nurse Anesthesia Pathway is clinically focused to prepare students for the full scope of Nurse Anesthesia practice. Graduates are prepared to promote evidence-based practice, patient safety ...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The ...

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in ...

To help you get a better understanding about the UAB School of Nursing and our DNP Nurse Anesthesia Pathway, we will be offering both an in-person and virtual open house where you will have the ...

Ronald Taylor is a director of Actavis and Red Lion Hotels Corp. In 1987, Mr Taylor founded Pyxis Corporation where he served as chair, president and chief executive officer until its purchase by ...